Hamlet Pharma Q4 Year-end Report July 2022-June 2023 >>
Read More
Hamlet Pharma AB (publ) (“Bolaget”) har genomfört namnbyte till Hamlet BioPharma AB (publ), vilket röstades igenom på extra bolagsstämman som avhölls den 11 augusti 2023….
Pressmeddelande Malmö 11 augusti 2023 Som tidigare meddelats har Bolagsverket registrerat fusionen mellan Hamlet Pharma och SelectImmune Pharma. Detta innebär att Hamlet Pharma och SelectImmune Pharma…
Bolagsverket har nu lämnat tillstånd till Hamlet Pharma AB (publ) (”Hamlet Pharma”) och SelectImmune Pharma AB (publ) (”SelectImmune”) att verkställa fusionen mellan de två bolagen….
Aktieägarna i Hamlet Pharma AB (publ) (”Hamlet Pharma” eller ”Bolaget”), 556568-8958, kallas härmed till extra bolagsstämma onsdagen den 11 augusti 2023 kl. 11:00 i i…
FDA Clearance of IND Application for Alpha1H for the treatment of non-muscle invasive bladder cancer
Hamlet Pharma is proud to announce today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for Alpha1H,…
Hamlet Pharma, soon to be Hamlet BioPharma, the innovative pharmaceutical company with several projects in Phase II trials in infection and cancer and an extensive…
Lund, June 12, Hamlet Pharma, ticker HAMLET, soon to be Hamlet BioPharma, the innovative pharmaceutical company with a strong portfolio of projects for the treatment…
Lund, June 9, Hamlet Pharma soon to be Hamlet BioPharma, the innovative pharmaceutical company with a strong portfolio of projects for the treatment of cancer…
Hamlet Pharma AB (publ) (”Hamlet Pharma” eller “Bolaget”) meddelar idag utfallet från nyttjandet av teckningsoptionerna av serie TO 4 B, vilka emitterades under 2021. Totalt…
Lund, May 31, Hamlet Pharma soon to be Hamlet BioPharma, the innovative pharmaceutical company with a strong portfolio of projects for the treatment of cancer…
Opening remarks During the third quarter of the fiscal year, Hamlet Pharma has continued its clinical trial program for Alpha1H, a drug candidate in the…